Literature DB >> 2856877

Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases.

M E Kraenzlin, J L Ch'ng, S M Wood, D H Carr, S R Bloom.   

Abstract

A 43-yr-old-man with metastatic VIPoma in whom the conventional measures of surgery, chemotheraphy, and hepatic artery embolization ultimately failed to control his severe diarrhea, resulting from vasoactive intestinal polypeptide hypersecretion, was treated with a new long-acting somatostatin analogue, SMS 201-995, for 14 mo. SMS 201-995 not only controlled the diarrhea without side effects but appeared to have possibly induced a reduction in metastatic tumor size.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2856877     DOI: 10.1016/s0016-5085(85)80153-0

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  42 in total

Review 1.  Genetics of pancreatic neuroendocrine tumors: implications for the clinic.

Authors:  Antonio Pea; Ralph H Hruban; Laura D Wood
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-09-28       Impact factor: 3.869

2.  Vasoactive intestinal polypeptide-secreting tumor (VIPoma) with liver metastases: dramatic and durable symptomatic benefit from hepatic artery embolization, a case report.

Authors:  C C Case; K Wirfel; R Vassilopoulou-Sellin
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

Review 3.  Treatment of pancreatic cancer. Promises and problems of tamoxifen, somatostatin analogs, and gemcitabine.

Authors:  L Rosenberg
Journal:  Int J Pancreatol       Date:  1997-10

4.  Treatment of pancreatic cholera.

Authors:  H Hagege; C Buffet; G Pelletier; A Roche; J P Etienne
Journal:  Dig Dis Sci       Date:  1988-01       Impact factor: 3.199

5.  Four year treatment with a long acting somatostatin analogue in a patient with Verner-Morrison syndrome.

Authors:  A Brunani; C Crespi; M De Martin; A Dubini; M Piolini; F Cavagnini
Journal:  J Endocrinol Invest       Date:  1991-09       Impact factor: 4.256

6.  Chronic treatment with a long-acting somatostatin analogue in a patient with intestinal carcinoid tumor: occurrence of cholelithiasis.

Authors:  E Roti; R Minelli; E Gardini; M Salvi; L Bianconi; L Balducci; A Manfredi; L E Braverman
Journal:  J Endocrinol Invest       Date:  1990-01       Impact factor: 4.256

Review 7.  Pancreatic cancer: a review of emerging therapies.

Authors:  L Rosenberg
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

8.  Development of a meningioma in a patient with acromegaly during octreotide treatment: are there any causal relationships?

Authors:  E De Menis; G Tulipano; S Villa; D Billeci; C Bonfanti; P Pollara; P Pauletto; A Giustina
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

Review 9.  Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.

Authors:  Nitya Raj; Diane Reidy-Lagunes
Journal:  Hematol Oncol Clin North Am       Date:  2015-10-23       Impact factor: 3.722

10.  Amelioration of symptoms and reduction of VIP levels after hepatic artery chemoembolization in a patient with sandostatin resistant VIPoma.

Authors:  Walid Shaib; Kisha Mitchell; M Wasif Saif
Journal:  Yale J Biol Med       Date:  2010-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.